Systematic Transplantectomy Versus Conventional Care After Kidney Graft Failure (DESYRE)

  • End date
    Nov 25, 2023
  • participants needed
  • sponsor
    Hospices Civils de Lyon
Updated on 25 March 2022
immunosuppressive agents
graft failure


Our hypothesis is early and systematic transplantectomy under a well-conducted immunosuppression is associated with a decreased risk of anti-HLA immunization against a conservative attitude including a gradual reduction of immunosuppression, with or without a transplantectomy performed for cause (clinical event).

Observation or Investigation Method Used :

The study is :

  • multicenter
  • prospective
  • open
  • randomized: patients are divided into two parallel groups:
  • study group: transplantectomy within six weeks after return to dialysis, antiproliferatives stop at the start of dialysis, Maintenance anticalcineurin-based-immunosuppression without dose reduction up to two weeks after transplantectomy. Abrupt discontinuation of anticalcineurin two weeks after transplantectomy. Corticosteroids: 5mg per day until one month after transplantectomy then stop within one month.
  • control group: No systematic transplantectomy. Antiproliferatives stop at the start of dialysis.Anticalcineurins half dose for 3 months, ¼ dose for 3 months and then stop. Corticosteroids:5 mg per day for 6 months, and then tapered and stop within 3 months.

In the case of transplantectomy for cause in the control group, immunosuppression will be continued at the maintenance dose during the current surgical procedure, and withdrawn two weeks later,similary to systematic transplantectomy.

Condition Renal Transplantation
Treatment Systematic transplantectomy, Progressive reduction of immunosuppression
Clinical Study IdentifierNCT01817504
SponsorHospices Civils de Lyon
Last Modified on25 March 2022


Yes No Not Sure

Inclusion Criteria

Age ≥ 18 Years
Patients affiliated to health protection system, social security in France or any similar regimen
Renal transplant patient with end-stage transplantation, regardless of the number of previous transplants
Patient receiving immunosuppressive protocol based on anticalcineurin or mTOR inhibitors
Patient should have resume hemodialysis within 4 weeks
Duration of transplantation more than one year
Patient with asymptomatic graft
immunogenic potential residual >50% (calculated PIR during the re-dialysis)
Patient not covered by any measure of legal protection

Exclusion Criteria

Immunogenic potential residual <50%
Graft infection uncontrolled by treatment
Active infectious pathology
Inflammatory graft
Uncontrolled arterial hypertention
Inflammatory syndrome of undetermined origin with CRP>50mg/l
Fever of unknown origin for more than 8 days T>38°C
Contra-indication to surgery
AVK treatment
Patient candidate for a living donor within 12 months
Monotherapy with calcineurin inhibitors or mTOR inhibitors
Treatment directed against the humoral response in the 6 months preceding the recovery of dialysis (Rituximab IV-Ig or high doses)
Presence of another transplant (pancreas, liver, heart, lung)
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note